financetom
Business
financetom
/
Business
/
Update: Nvidia Fiscal Q3 Non-GAAP Earnings, Revenue Rise; Q4 Outlook Set
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Nvidia Fiscal Q3 Non-GAAP Earnings, Revenue Rise; Q4 Outlook Set
Nov 20, 2024 7:41 PM

05:02 PM EST, 11/20/2024 (MT Newswires) -- (Updates the stock change in the last paragraph.)

Nvidia ( NVDA ) reported fiscal Q3 non-GAAP earnings late Wednesday of $0.81 per diluted share, up from $0.40 a year earlier.

Analysts polled by FactSet expected $0.75 excluding some items.

Revenue in the three months ended Oct. 27 rose to $35.08 billion from $18.12 billion a year earlier.

Analysts surveyed by FactSet expected $33.17 billion.

The company expects fiscal Q4 revenue of $37.5 billion, plus or minus 2%. Analysts expect $37.09 billion.

Nvidia ( NVDA ) shares fell 0.7% in after-hours activity, paring earlier losses.

Price: 144.81, Change: -1.08, Percent Change: -0.74

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
ServiceNow 'Well-positioned' to Sustain 20% Subscription Growth, Morgan Stanley Says
ServiceNow 'Well-positioned' to Sustain 20% Subscription Growth, Morgan Stanley Says
Sep 24, 2025
10:08 AM EDT, 09/24/2025 (MT Newswires) -- ServiceNow ( NOW ) is well-positioned to sustain a 20% subscription increase and drive more than 20% free cash flow growth through fiscal 2027, analysts at Morgan Stanley said in a note Wednesday. ServiceNow's ( NOW ) overall business fundamentals have remained sound despite a volatile backdrop, delivering subscription revenue growth of about...
Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short
Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short
Sep 24, 2025
Acadia Pharmaceuticals Inc. ( ACAD ) released topline results on Wednesday from its Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients with hyperphagia in Prader-Willi syndrome (PWS). PWS is a rare genetic disorder characterized by muscle weakness and feeding difficulties in infancy, followed by an insatiable hunger and tendency toward severe obesity...
Integral Ad Science to Be Taken Private by Novacap in $1.9 Billion Deal; Shares Surge
Integral Ad Science to Be Taken Private by Novacap in $1.9 Billion Deal; Shares Surge
Sep 24, 2025
10:03 AM EDT, 09/24/2025 (MT Newswires) -- Shares of Integral Ad Science ( IAS ) soared on Wednesday after the digital ad verification company agreed to be acquired and taken private by Novacap in an all-cash deal worth $1.9 billion. Shareholders of media measurement and optimization platform Integral Ad Science ( IAS ) will receive $10.30 per share from the...
Coast Copper Shares Rise After Selling Borealis Property in B.C. to Hi-View Resources
Coast Copper Shares Rise After Selling Borealis Property in B.C. to Hi-View Resources
Sep 24, 2025
10:08 AM EDT, 09/24/2025 (MT Newswires) -- Coast Copper ( COCCF ) shares rose 5.3% Wednesday after it completed the sale of its Borealis property located in the Toodoggone District in northcentral British Columbia, to Hi-View Resources ( HVWRF ) . Hi-View acquired a 100% interest in its Borealis property, by paying $500,000 in cash, issuing 3.5 million Hi-View common...
Copyright 2023-2026 - www.financetom.com All Rights Reserved